12/17
07:06 am
glue
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
High
Report
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
12/16
07:10 am
glue
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations [Yahoo! Finance]
Medium
Report
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations [Yahoo! Finance]
12/16
07:00 am
glue
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations
Medium
Report
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations
12/15
04:15 pm
glue
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results [Yahoo! Finance]
High
Report
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results [Yahoo! Finance]
12/15
04:01 pm
glue
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
High
Report
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
12/11
02:10 pm
glue
Novartis and UK-based Relation forge R&D deal worth up to $1.7bn [Yahoo! Finance]
Low
Report
Novartis and UK-based Relation forge R&D deal worth up to $1.7bn [Yahoo! Finance]
12/11
04:18 am
glue
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
11/30
04:41 am
glue
Monte Rosa: Looking Mispriced After Big Pharma Validation [Seeking Alpha]
Medium
Report
Monte Rosa: Looking Mispriced After Big Pharma Validation [Seeking Alpha]
11/8
02:14 pm
glue
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases [Yahoo! Finance]
High
Report
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases [Yahoo! Finance]
11/8
11:30 am
glue
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
High
Report
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
11/7
01:43 pm
glue
Monte Rosa Therapeutics (NASDAQ:GLUE) had its price target raised by analysts at Wells Fargo & Company from $10.00 to $13.00. They now have an "equal weight" rating on the stock.
Low
Report
Monte Rosa Therapeutics (NASDAQ:GLUE) had its price target raised by analysts at Wells Fargo & Company from $10.00 to $13.00. They now have an "equal weight" rating on the stock.
11/6
07:00 am
glue
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
Medium
Report
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
11/3
07:00 am
glue
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
10/31
01:04 pm
glue
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
10/24
07:00 am
glue
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
Medium
Report
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
9/30
12:00 pm
glue
Pallas Capital Backs Monte Rosa Therapeutics, Inc. (GLUE) Amid Growth Prospects [Yahoo! Finance]
Low
Report
Pallas Capital Backs Monte Rosa Therapeutics, Inc. (GLUE) Amid Growth Prospects [Yahoo! Finance]